Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.

Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients

Phase 3

Completed

Conditions: Major Depression

Interventions: Drug: quetiapine
Drug: escitalopram

First Posted Date: 2009-08-06

Last Posted Date: 2013-02-12

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 60

Registration Number: NCT00953108

Locations: 🇩🇪
Department of Psychiatry, Ludwig-Maximilian-University, Munich, Bavaria, Germany

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

Phase 4

Completed

Conditions: Psychotic Disorders

Interventions: Drug: Olanzapine
Drug: Quetiapine
Drug: Risperidone
Drug: Ziprasidone

First Posted Date: 2009-07-03

Last Posted Date: 2010-05-25

Lead Sponsor: University of Bergen

Target Recruit Count: 226

Registration Number: NCT00932529

Locations: 🇳🇴
Haukeland University Hospital, Division of Psychiatry, Bergen, Sandviken, Norway

Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR

Phase 3

Conditions: BIPOLAR DISORDER

Interventions: Drug: quetiapine

First Posted Date: 2009-04-10

Last Posted Date: 2011-02-16

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 100

Registration Number: NCT00879307

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil

A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Quetiapine
Drug: risperidone

First Posted Date: 2009-01-06

Last Posted Date: 2010-06-15

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 120

Registration Number: NCT00817648

Locations: 🇨🇳
Mental Health Center of Luwan District, Shanghai, Shanghai, China
🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
🇨🇳
Branch Hospital of Shanghai Mental Health Center, Shanghai, Shanghai, China

and more 1 locations